Janssen, J.
Staal, F. H. E.
Brouwer, C. L.
Langendijk, J. A.
de Jong, I. J.
van Moorselaar, R. J. A.
Schuit, E.
Verzijlbergen, J. F.
Smeenk, R. J.
Aluwini, S.
Funding for this research was provided by:
KWF Kankerbestrijding (12448)
Article History
Received: 18 February 2022
Accepted: 8 April 2022
First Online: 2 May 2022
Declarations
:
: The Dutch Central Committee on Research Involving Human Subjects (CCMO) and the accredited Medical Ethical Committee (METc) have provided approval for the conduct of this study (NL70897.042.19, CCMO 26–11-2019 | METc 05–02-2020). Written informed consent of patients is required before enrolment in the trial and before any study-related procedures take place. Patients may voluntarily withdraw from study participation at any time for any reason. The investigator can decide to withdraw a patient from the study for urgent medical reasons.
: Not applicable.
: The authors declare that they have no competing interests.